Loading clinical trials...
Loading clinical trials...
This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more
NCT04469439 · Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
NCT04530383 · Cystic Fibrosis-related Diabetes, Cystic Fibrosis
NCT06154447 · Cystic Fibrosis
NCT05422222 · Cystic Fibrosis
Royal Adelaide Hospital
Adelaide
The Prince Charles Hospital
Chermside
Alfred Hospital
Melbourne, VIC
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions